Citadel Advisors’s Edgewise Therapeutics EWTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.26M | Buy |
325,249
+227,971
| +234% | +$2.99M | ﹤0.01% | 2061 |
|
|
2025
Q1 | $2.14M | Sell |
97,278
-372,173
| -79% | -$8.19M | ﹤0.01% | 2529 |
|
|
2024
Q4 | $12.5M | Sell |
469,451
-68,798
| -13% | -$1.84M | ﹤0.01% | 1186 |
|
|
2024
Q3 | $14.4M | Sell |
538,249
-1,810,925
| -77% | -$48.3M | ﹤0.01% | 1047 |
|
|
2024
Q2 | $42.3M | Sell |
2,349,174
-370,117
| -14% | -$6.67M | 0.01% | 548 |
|
|
2024
Q1 | $49.6M | Buy |
2,719,291
+133,361
| +5% | +$2.43M | 0.01% | 489 |
|
|
2023
Q4 | $28.3M | Sell |
2,585,930
-181,506
| -7% | -$1.99M | 0.01% | 703 |
|
|
2023
Q3 | $15.9M | Buy |
2,767,436
+92,446
| +3% | +$530K | ﹤0.01% | 899 |
|
|
2023
Q2 | $20.7M | Sell |
2,674,990
-93,448
| -3% | -$724K | ﹤0.01% | 800 |
|
|
2023
Q1 | $18.5M | Sell |
2,768,438
-78,081
| -3% | -$521K | ﹤0.01% | 889 |
|
|
2022
Q4 | $25.4M | Buy |
2,846,519
+84,795
| +3% | +$758K | 0.01% | 753 |
|
|
2022
Q3 | $27.2M | Buy |
2,761,724
+223,706
| +9% | +$2.2M | 0.01% | 658 |
|
|
2022
Q2 | $20.2M | Sell |
2,538,018
-101,782
| -4% | -$810K | 0.01% | 836 |
|
|
2022
Q1 | $25.6M | Buy |
2,639,800
+181,359
| +7% | +$1.76M | 0.01% | 759 |
|
|
2021
Q4 | $37.6M | Buy |
2,458,441
+33,257
| +1% | +$508K | 0.01% | 614 |
|
|
2021
Q3 | $40.3M | Sell |
2,425,184
-34,967
| -1% | -$580K | 0.01% | 544 |
|
|
2021
Q2 | $51.2M | Buy |
2,460,151
+78,003
| +3% | +$1.62M | 0.01% | 480 |
|
|
2021
Q1 | $77.4M | Buy |
+2,382,148
| New | +$77.4M | 0.02% | 296 |
|